Hudson Bay Capital Management
IMDX

Hudson Bay Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Hudson Bay Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,061
Closed -$98K – 1536
2025
Q4 		$98K Buy
+13,061
New +$73.7K ﹤0.01% 1027

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Hudson Bay Capital Management's IMDX Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q1 2026, closing a stake of 13,061 shares — an estimated $98K sold.

Hudson Bay Capital Management first reported a position in IMDX in Q4 2025 and held it in 1 quarter. The position peaked at $98K in Q4 2025. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Insight Molecular Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 13,061 Insight Molecular Diagnostics shares in Q1 2026, an estimated $98K.
  • Hudson Bay Capital Management first reported a position in Insight Molecular Diagnostics in Q4 2025 and held it in 1 quarter.
  • Hudson Bay Capital Management's Insight Molecular Diagnostics position peaked at $98K in Q4 2025.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.